This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer® RNA-editing platform technology.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… immense, says Bart Klein, who was at the forefront of the Axiomer® technology development. ProQR’s Sr. Vice President Innovation makes his point about the promise of Axiomer® technology: “This opens up a whole new way of …
… ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple … ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple …
Partnerships in our industry are very common as companies look to benefit from knowledge and resource sharing. In this blog we explore why companies, like ProQR, partner with other companies.
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …
… in the lives of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing … nucleotides in RNA using the cells own editing machinery. Axiomer® RNA editing technology harnesses ADAR (Adenosine …
